Harmony Biosciences Holdings Inc (NASDAQ: HRMY) shares fell almost 20% after Scorpion Capital filed a Citizen's Petition with the FDA requesting the withdrawal of approval of Wakix (pitolisant). "With ...
Investing.com - Harmony Bio (NASDAQ: HRMY) reported second quarter EPS of $0.92, $0.20 better than the analyst estimate of $0.72. Revenue for the quarter came in at $200.5M versus the consensus ...
Hosted on MSN
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.
Biotech stocks put up a split showing at the J.P. Morgan Healthcare Conference in San Francisco, where names like BridgeBio Pharma, ARS Pharmaceuticals and Harmony Biosciences stood out with strong ...
Deal includes potential additional payments of up to $140 million. Harmony Biosciences has revealed a definitive agreement to obtain Zynerba Pharmaceuticals, a company focused on pharmaceutically ...
Harmony Biosciences (NASDAQ:HRMY) traded higher in the premarket Friday after Citi launched its coverage with a Buy rating and a $48 per share target, noting that with little credit attributed to its ...
*The Next Generation Collagen Laser Facial for glowing, smoother, firmer skin* The author, podcaster and TV personality Susannah Constantine, 63, opens up about confidence, ageing, and why she chose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback